ACADIA Pharmaceuticals Inc. vs MobilEye Global Inc — how do they compare? ACADIA Pharmaceuticals Inc. trades at $29.55 (market cap $5.07B), while MobilEye Global Inc trades at $8.9 (market cap $7.54B). The key difference: MobilEye Global Inc is the larger of the two by market cap, and ACADIA Pharmaceuticals Inc. is trading nearer its 52-week high, MobilEye Global Inc nearer its low. Which is the better fit depends on your goals.
| ACAD | MBLY | |
|---|---|---|
Market Cap | $5.07B | $7.54B |
Sector | Health | Technology |
52-Week High | $29.41 | $15.54 |
52-Week Low | $20.06 | $6.56 |
Enterprise Value | $4.19B | $6.10B |
Trailing returns across standard periods
Latest headlines on both assets
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →Mobileye Global Inc. is a global leader in the development and deployment of Advanced Driver Assistance Systems (ADAS) and autonomous driving technologies. The company specializes in computer vision, machine learning, and data analysis to create sensing, mapping, and driving policy solutions. Mobileye's technology, including its EyeQ system-on-chips and its crowd-sourced mapping platform (REM), is integrated into vehicles worldwide, aiming to improve road safety and enable the future of autonomous mobility.
Read more on MBLY →